导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.76% | 1521/4773 |
| 近一周 | -2.54% | 2502/5462 |
| 近一月 | -4.95% | 2897/5421 |
| 近一季 | -8.80% | 2962/5209 |
| 近半年 | -6.44% | 3086/4920 |
| 近一年 | 7.67% | 1274/4366 |
| 近两年 | 70.16% | 967/2954 |
| 近三年 | 36.44% | 821/2253 |
| 成立以来 | 151.49% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.92% 1133/4961 |
18.52% 1370/5312 |
- - |
- - |
| 2025 | 30.83% 1284/4813 |
2.13% 1459/3635 |
1.88% 2052/4076 |
24.52% 1454/4524 |
0.97% 1629/4813 |
| 2024 | 6.38% 1762/3463 |
-2.60% 1386/2808 |
-5.09% 1643/3014 |
15.79% 1621/3129 |
-0.62% 1483/3463 |
| 2023 | -5.73% 766/2656 |
7.66% 539/2280 |
-4.06% 1031/2385 |
-4.53% 1158/2515 |
-4.40% 1010/2655 |
| 2022 | -17.46% 593/2207 |
-13.28% 725/1919 |
3.38% 1161/2016 |
-10.41% 400/2113 |
2.77% 842/2208 |
| 2021 | 16.49% 266/1822 |
-1.68% 528/1255 |
9.38% 556/1330 |
4.72% 324/1466 |
3.45% 432/1822 |
| 2020 | 23.41% 655/1250 |
-4.40% 364/1028 |
16.72% 419/1067 |
7.04% 805/1164 |
3.33% 923/1184 |
| 2019 | 26.19% 581/1092 |
30.63% 239/754 |
-9.72% 683/804 |
0.38% 522/850 |
6.59% 583/918 |
| 2018 | -30.76% 477/834 |
- - |
- - |
- - |
-12.02% 396/691 |
| 2017 | 0.64% 472/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.19% 351/605 |
- - |
- - |
- - |
- - |
| 2015 | 44.14% 35/575 |
- - |
- - |
- - |
- - |
| 2014 | 36.33% 142/237 |
- - |
- - |
- - |
- - |
| 2013 | 16.05% 23/186 |
- - |
- - |
- - |
- - |
| 2012 | -0.17% 119/140 |
- - |
- - |
- - |
- - |
| 2011 | -32.71% 97/102 |
- - |
- - |
- - |
- - |
| 2010 | 9.47% 3/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方中证500ETF联接(LOF)A VS. 长安沪深300非周期A(740101) |